首页 | 本学科首页   官方微博 | 高级检索  
     


Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis
Authors:Ralf Spitthöver  Tilmann Röseler  Ulrich Julius  Franz Heigl  Volker J. J. Schettler  Ralf Kühn  Josef Leebmann  Andrea Raabe  Markus Knittel  Carsten Schürfeld  Michael Moesenthin  Wanja M. Bernhardt  Eberhard Röseler  Markus Ketteler  Andreas Heibges  Reinhard Klingel
Affiliation:1. Dialysis and Lipid Center North Rhine, Essen, Germany;2. Center for Nephrology, Hypertension, and Metabolic Diseases, Hannover, Germany;3. 3rd Medical Clinic, University Hospital at the Technische Universität, Dresden, Germany;4. Medical Health and Care Center Kempten-Allgäu, Kempten, Germany;5. Center for Nephrology, Göttingen, Germany;6. Clinic for Nephrology and Dialysis, Tangermünde, Germany;7. Interdisciplinary Apheresis Center at Passau General Hospital, Passau, Germany;8. Clinic for Nephrology, General Hospital, Coburg, Germany;9. Center for Dialysis and Apheresis, Witten, Germany;10. Center for Nephrology and Dialysis, Saarlouis, Germany;11. Apheresis Research Institute, Cologne, Germany
Abstract:
Keywords:coronary artery disease  hypercholesterolemia  lipoprotein apheresis  lipoprotein(a)  low-density lipoprotein cholesterol  PCSK9 antibodies
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号